• Markets
    • icon
  • Companies
PYC · ASX

PYC Therapeutics Limited (ASX:PYC)

AU$0.1

 0.0 (0.0%)
ASX:Live
26/07/2024 04:10:15 PM
HALO Ords HALO Consensus Value GROWTH AUS All-Consensus All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

PYC Overview

PYC Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Strong

Earnings

Neutral

Growth

Earnings

Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Weak

About PYC

Website

PYC Therapeutics Limited

Telephone

61.8.6151.0992

Address

6 Verdun Street Harry Perkins Institute Nedlands, Western Australia (WA) 6009

Description

PYC Therapeutics Ltd. is a drug-development company, which provides a new generation of RNA therapeutics to meet unmet need in disease. It develops intracellular biological therapeutics including its own preclinical oncology payloads, using its proprietary cell Functional Penetrating Phylomers. The company was founded by Richmond Miles Hopkins and Paul Michael Watt on October 9, 2001, and is headquartered in Nedlands, Australia.

PYC Price Chart

Key Stats

Market Cap

AU$491.92M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.05 - 0.14

Trade Value (12mth)

AU$49,692.00

1 week

-4.55%

1 month

-16%

YTD

6.25%

1 year

77.08%

All time high

0.65

Key Fundamentals

EPS 3 yr Growth

184.000%

EBITDA Margin

N/A

Operating Cashflow

-$24m

Free Cash Flow Return

-71.90%

ROIC

-67.10%

Interest Coverage

-1,402.90

Quick Ratio

3.80

Other Data

Shares on Issue (Fully Dilluted)

3777m

HALO Sector

Healthcare

Next Company Report Date

27-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

PYC Announcements

Latest Announcements

Date Announcements

23 July 24

Extension of RP11 Single Dose Study Into Multiple Dose Study

×

Extension of RP11 Single Dose Study Into Multiple Dose Study

22 July 24

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

17 July 24

Initial Dosing Completed in Cohort 1 of RP11 MAD Study

×

Initial Dosing Completed in Cohort 1 of RP11 MAD Study

12 July 24

Bioshares Biotech Summit Presentation

×

Bioshares Biotech Summit Presentation

10 July 24

Commencement of RP11 Multiple Dose Trial

×

Commencement of RP11 Multiple Dose Trial

02 July 24

Notification regarding unquoted securities - PYC

×

Notification regarding unquoted securities - PYC

01 July 24

RP11 Drug Candidate Safe and Well Tolerated

×

RP11 Drug Candidate Safe and Well Tolerated

07 June 24

PMS Drug Candidate Effective In Human Brain Cells

×

PMS Drug Candidate Effective In Human Brain Cells

24 May 24

Small Shareholdings Sale Facility

×

Small Shareholdings Sale Facility

24 May 24

US FDA Grants Orphan Drug Designation to PYC Drug Candidate

×

US FDA Grants Orphan Drug Designation to PYC Drug Candidate

23 May 24

Notification regarding unquoted securities - PYC

×

Notification regarding unquoted securities - PYC

23 May 24

Issue of Options

×

Issue of Options

17 May 24

Change of Director's Interest Notice

×

Change of Director's Interest Notice

17 May 24

Change in substantial holding

×

Change in substantial holding

16 May 24

RP11 Clinical Trial Dosing Completed in Cohort 4

×

RP11 Clinical Trial Dosing Completed in Cohort 4

14 May 24

Successful GLP Tox Studies in Second Blinding Eye Disease

×

Successful GLP Tox Studies in Second Blinding Eye Disease

09 May 24

Q2 2024 Investor Webinar Presentation

×

Q2 2024 Investor Webinar Presentation

06 May 24

Presentation of RP11 Clinical Trial Data at ARVO Conference

×

Presentation of RP11 Clinical Trial Data at ARVO Conference

01 May 24

Q2 Investor Webinar 9 May 2024

×

Q2 Investor Webinar 9 May 2024

01 May 24

Ceasing to be a substantial holder

×

Ceasing to be a substantial holder

30 April 24

Application for quotation of securities - PYC

×

Application for quotation of securities - PYC

29 April 24

RP11 Drug Candidate Progressing to Mid-Stage Human Trials

×

RP11 Drug Candidate Progressing to Mid-Stage Human Trials

26 April 24

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

22 April 24

Kidney Disease Drug Candidate Progressing to Human Trials

×

Kidney Disease Drug Candidate Progressing to Human Trials

17 April 24

Change in substantial holding

×

Change in substantial holding

PYC Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.01 -0.00 -0.01 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.01 -0.00 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock -132.0 24.1 -61.4 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.00 -0.00 -0.01 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.00 -0.01 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock -130.0 10.7 -62.9 Lock Lock Lock
     Yield % Lock Lock Lock Lock -2.6 -10.7 -13.9 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.02 0.01 0.01 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.02 0.01 0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock 90.4 -27.9 -37.3 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 3,092 3,181 3,211 Lock Lock Lock
Basic m Lock Lock Lock Lock 3,092 3,181 3,211 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 21 29 38 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock -1 -1 -1 Lock Lock Lock
     Growth % Lock Lock Lock Lock -13.8 -34.9 -5.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -21 -29 -38 Lock Lock Lock
     Growth % Lock Lock Lock Lock -131.7 -38.5 -30.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 1 1 1 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -22 -30 -39 Lock Lock Lock
     Growth % Lock Lock Lock Lock -125.0 -38.4 -29.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -22 -30 -39 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -3 -16 -16 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -18 -14 -23 Lock Lock Lock
     Growth % Lock Lock Lock Lock -160.4 22.0 -64.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -12 -22 -24 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 1 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock -16 33 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 39 0 11 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -12 -22 -25 Lock Lock Lock
     Growth % Lock Lock Lock Lock -111.5 -79.0 -12.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 52 29 16 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 58 45 37 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 1 1 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -51 -28 -15 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 4 5 9 Lock Lock Lock
Equity $m Lock Lock Lock Lock 53 39 28 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 54 40 28 Lock Lock Lock
     Growth % Lock Lock Lock Lock 84.2 -25.3 -30.3 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -30.7 -30.6 -61.3 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -33.5 -35.2 -82.1 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -51.0 -63.1 -112.0 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -43.2 -29.6 -67.1 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -28.7 -46.5 -71.9 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock -546.4 -901.0 -1,402.9 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 2.4 1.0 0.4 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -95.7 -71.6 -55.0 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 15.7 8.9 3.8 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 15.7 8.9 3.8 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 99.5 74.2 48.9 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -357.6 -496.4 -290.5 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -30.7 -30.6 -61.3 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.1 1.2 1.3 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -33.5 -35.2 -82.1 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -33.5 -35.2 -82.1 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 716.5 1,069.8 1,550.6 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -716.5 -1,069.8 -1,550.6 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

PYC Shortsell

Frequently Asked Questions

The current share price of PYC Therapeutics Limited (PYC:ASX) is AU$0.1.
The 52-week high share price for PYC Therapeutics Limited (PYC:ASX) is AU$0.14.
The 52-week low share price for PYC Therapeutics Limited (PYC:ASX)? is AU$0.05.
PYC Therapeutics Limited (PYC:ASX) does not pay a dividend.
PYC Therapeutics Limited (PYC:ASX) does not pay a dividend.
PYC Therapeutics Limited (PYC:ASX) has a franking level of 0.0%.
PYC Therapeutics Limited (PYC:ASX) is classified in the Healthcare.
The current P/E ratio for PYC Therapeutics Limited (PYC:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.